Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27472641 | 0.83 | CYP1A2 (0.51) | GAACYP1A2PKMPOLBCYP2C19 | |
| SCHEMBL30402495 | 0.81 | PKM (0.57) | GAACYP1A2PKMPOLBCYP2C19 | |
| SCHEMBL933269 | 0.81 | PKM (0.57) | GAACYP1A2PKMPOLBCYP2C19 | |
| SCHEMBL477465 | 0.80 | CYP2C19 (0.50) | GAACYP1A2PKMPOLBCYP2C19 | |
| SCHEMBL8993135 | 0.80 | MAPT (0.49) | GAACYP1A2PKMPOLBCYP2C19 | |
| SCHEMBL23634077 | 0.77 | PKM (0.74) | GAACYP1A2PKMPOLBCYP2C19 | |
| SCHEMBL10829560 | 0.76 | PKM (0.50) | GAACYP1A2PKMPOLBCYP2C19 | |
| SCHEMBL28254387 | 0.76 | PKM (0.56) | GAACYP1A2PKMPOLBCYP2C19 | |
| SCHEMBL2790806 | 0.75 | PKM (0.67) | GAACYP1A2PKMPOLBCYP2C19 | |
| SCHEMBL2103568 | 0.74 | MAPK1 (0.55) | GAACYP1A2KMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | BOLIN DAVID ROBERT | 2010-07-01 | — | — | US | disclosed |
| US-7714126-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| CN-101316844-A | Inhibitors of diacylglycerol acyltransferase (DGAT) | HOFFMANN LA ROCHE (CH) | 2008-12-03 | — | — | CN | disclosed |
| EP-1963313-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| CN-101103007-A | Amide compound | TAKEDA PHARMACEUTICAL (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GAA 200/4885CYP1A2 818/4885PKM 3122/4885 |
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | GAA 4430/4885CYP1A2 182/4885PKM 3762/4885 |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT2, DGAT1, LCAT | GAA 200/4885CYP1A2 818/4885PKM 3122/4885 |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | GAA 200/4885CYP1A2 818/4885PKM 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.